Skip to main content
Top
Published in: International Urology and Nephrology 3/2020

01-03-2020 | Antibiotic | Urology - Original Paper

The clinical rate of antibiotic change following empiric treatment for suspected urinary tract infections

Authors: Jonathan Dokter, Lauren E. Tennyson, Laura Nguyen, Esther Han, Larry T. Sirls

Published in: International Urology and Nephrology | Issue 3/2020

Login to get access

Abstract

Purpose

To determine the rate of antibiotic change in an outpatient setting following empiric treatment of culture proven UTI and to identify risk factors associated with change.

Methods

Patients with suspected UTI and urine culture were reviewed (January 2016–June 2016). Those with a positive culture were categorized by whether or not they were treated empirically. Empiric treatment was evaluated for associations with clinical–demographic data, symptoms and urinalysis (UA). Antibiotic change was evaluated with clinical–demographic data, urine culture, and resistance patterns.

Results

916 urine cultures (636 patients) were included. 391 (43%) cultures were positive, and 164 (42%) were treated empirically. Clinical–demographic data did not differ between groups. Those treated empirically had more documented UTI symptoms (93 vs 58%, P < 0.001), and UA abnormalities including positive nitrites (51 vs 29%, P < 0.001), 3 + leukocyte esterase (27 vs 19%, P = 0.002) and 3 + blood (13 vs 4%, P = 0.005). Of those treated empirically, 42/164 (26%) required an antibiotic change, and this was associated with immunosuppression (12 vs 2%, P = 0.027) resistance to > 3 antibiotics (33 vs 20%, P = 0.039) and also resistance to fluoroquinolone (50 vs 30%, P = 0.016), monobactam (19 vs 7% P = 0.042) and TMP–SMX (52 vs 19%, P < 0.001).

Conclusions

Almost one-quarter of patients treated empirically required antibiotic change. This was driven largely by bacterial resistance. New technologies allowing rapid bacterial identification and sensitivity may improve patient care.
Literature
1.
go back to reference CDC (2013) Antibiotic resistance threats in the United States, 2013. Current vol 114. Doi: CS239559-B, p 1 CDC (2013) Antibiotic resistance threats in the United States, 2013. Current vol 114. Doi: CS239559-B, p 1
5.
go back to reference American Urological Association (2010) National Urology Research Agenda American Urological Association (2010) National Urology Research Agenda
7.
go back to reference World Health Organization (2015) Global action plan on antimicrobial resistance. WHO Press, Geneva. pp 1–28. Doi: ISBN 978 92 4 150976 3 World Health Organization (2015) Global action plan on antimicrobial resistance. WHO Press, Geneva. pp 1–28. Doi: ISBN 978 92 4 150976 3
14.
go back to reference Croxall G, Weston V, Joseph S, Manning G, Cheetham P, McNally A (2011) Increased human pathogenic potential of Escherichia coli from polymicrobial urinary tract infections in comparison to isolates from monomicrobial culture samples. J Med Microbiol 60:102–109CrossRef Croxall G, Weston V, Joseph S, Manning G, Cheetham P, McNally A (2011) Increased human pathogenic potential of Escherichia coli from polymicrobial urinary tract infections in comparison to isolates from monomicrobial culture samples. J Med Microbiol 60:102–109CrossRef
Metadata
Title
The clinical rate of antibiotic change following empiric treatment for suspected urinary tract infections
Authors
Jonathan Dokter
Lauren E. Tennyson
Laura Nguyen
Esther Han
Larry T. Sirls
Publication date
01-03-2020
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2020
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02327-7

Other articles of this Issue 3/2020

International Urology and Nephrology 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine